Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary

Data suggests that favipiravir (FVP) could be used against SARS-CoV-2. Our aim was to investigate the role of FVP in COVID-19 treatment. A prospective sequential cohort study was performed among adults hospitalized at our center between March and August 2020 with moderate-to-severe, PCR-confirmed CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabo, Balint Gergely, Lenart, Katalin Szidonia, Petrik, Borisz, Gaspar, Zsofia, Kiss-Dala, Noemi, Szlavik, Janos, Valyi-Nagy, Istvan, Lakatos, Botond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413073/
https://www.ncbi.nlm.nih.gov/pubmed/34476717
http://dx.doi.org/10.1007/s11357-021-00452-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413073/
https://www.ncbi.nlm.nih.gov/pubmed/34476717
http://dx.doi.org/10.1007/s11357-021-00452-9

Ejemplares similares